Novartis India (NOVARTIND)

FairStock Score: 31/100 — RISKY

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• Near-zero leverage with debt/equity of 0.01, so no immediate financial distress risk
• ROCE of 17% and ROE of 13.33% indicate reasonable capital efficiency on existing operations
• Promoter holding of 70.68% aligns the controlling shareholder's interests with the company
• Dividend yield of 2.74% provides some income cushion despite the earnings decline

Concerns

• Revenue declined 7.63% and profit fell 36.78%, showing negative operating momentum
• Piotroski F-Score of 3/9 suggests weak financial health and deteriorating fundamentals
• P/E of 23.14 and P/B of 3.35 are expensive relative to declining earnings and book value of ₹293.98
• Latest quarter sales of ₹86 Cr and net profit of ₹16 Cr indicate the weak trend continues

AI Analysis

As a value investor, I first ask not what a business has done for me lately, but what it earns on capital and whether it can compound. On those tests, Novartis India concerns me. Revenue fell 7.63%, profit dropped 36.78%, and the Piotroski F-Score of 3/9 tells me the fundamentals are deteriorating. At ₹985.45, I am being asked to pay a P/E of 23.14 and a P/B of 3.35 against a book value of just ₹293.98. That is not a margin of safety; that is paying a rich multiple for a shrinking business. Benjamin Graham would call that speculation. The company does have strengths: debt-equity of 0.01, ROCE of 17%, ROE of 13.33%, and promoter holding of 70.68%, which aligns ownership. The 2.74% dividend yield offers some cushion, but it does not compensate for a 36.78% profit decline. The latest quarter, with sales of ₹86 Cr and net profit of ₹16 Cr, shows operating momentum is still weak. The stock is 44% below its 52-week high of ₹1780; that may look tempting, but a falling knife often has further to fall. FairStock Score of 9/100 is a clear red flag. I would need to see evidence that sales have stopped declining, margins are stabilizing, and the F-Score improves before considering an entry. This is not a stalwart or a smooth slow grower; it is a turnaround situation with execution risk. If the parent can rationalise costs, revive the portfolio, and improve capital allocation, there is potential. But as a minority investor, I should wait for the turn to appear in the numbers, not hope. Price changes daily; earning power and balance-sheet health take quarters. Let the data prove itself first.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer